
CRNX Earnings
Crinetics Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Crinetics Pharmaceuticals Inc(CRNX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Crinetics Pharmaceuticals Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-08-07 | After Hours | -1.13 | - | - | 5.10M | - | - | - | - |
FY2025Q1 | 2025-05-08 | After Hours | -0.99 | -1.04 | -5.05 | 100.00K | 361.00K | +261.00 | -6.18 | -4.31 |
FY2024Q4 | 2025-02-27 | After Hours | -0.92 | -0.88 | +4.35 | 727.27K | 0.00 | -100.00 | +7.74 | +2.71 |
FY2024Q2 | 2024-08-08 | After Hours | -0.86 | -0.94 | +9.30 | 467.27K | 399.00K | -14.61 | -6.11 | +3.53 |
FY2024Q1 | 2024-05-09 | - | -0.84 | -0.93 | -10.71 | 181.82K | 640.00K | +252.00 | -2.89 | -0.79 |
FY2023Q4 | 2024-02-28 | - | -0.89 | -0.90 | -1.12 | 182.89K | - | - | +5.66 | +6.08 |
FY2023Q3 | 2023-11-07 | - | -0.89 | -1.01 | -13.48 | 141.14K | 346.00K | +145.15 | -3.18 | -7.25 |
FY2023Q2 | 2023-08-08 | - | -0.85 | -0.94 | -10.59 | 1.28M | 988.00K | -22.80 | -3.89 | -6.44 |
- | 2023-05-04 | - | -0.82 | -0.85 | -3.66 | - | - | - | -0.93 | +8.21 |
- | 2023-02-28 | - | -0.82 | -0.84 | -2.44 | - | - | - | +2.19 | -1.82 |
CRNX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Crinetics Pharmaceuticals Inc reported performance for FY2025Q2, announced on 2025-08-07. The company achieved an EPS of , compared to analyst estimates of -1.13 by % . Revenue for the quarter reached 0.00 compared to expectations of 5.10M by % .
The stock price reacted with a % one-day change and a % five-day change following the earnings release. These movements reflect market reaction in Crinetics Pharmaceuticals Inc growth trajectory and strategic initiatives.
CRNX Earnings Forecast
Looking ahead, Crinetics Pharmaceuticals Inc(CRNX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 485.79K and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -11.09%, while EPS estimates have been Revise Upward by 52.32%. For the upcoming , revenue estimates have been adjusted Go Down by -12.46% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Crinetics Pharmaceuticals Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between CRNX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward

-11.09%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Upward

+52.32%
In Past 3 Month
Stock Price
Go Down

-12.46%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:5.12M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price29.23
CRNX Revenue and EPS Performance: A Historical Perspective
Crinetics Pharmaceuticals Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-08-07,After Hours):
EPS: (Actual) vs.-1.13 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 5.10M (Estimate) (%)
Price Reaction: %(1-Day), %(5-Day)
FY2025Q1 (2025-05-08,After Hours):
EPS: -1.04 (Actual) vs.-0.99 (Estimate) (-5.05%)
Revenue: 361.00K (Actual) vs. 100.00K (Estimate) (261.00%)
Price Reaction: -6.18%(1-Day), -4.31%(5-Day)
FY2024Q4 (2025-02-27,After Hours):
EPS: -0.88 (Actual) vs.-0.92 (Estimate) (4.35%)
Revenue: 0.00 (Actual) vs. 727.27K (Estimate) (-100.00%)
Price Reaction: 7.74%(1-Day), 2.71%(5-Day)
Earnings Reaction
The chart below shows how CRNX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CRNX sees a -2.91% change in stock price 10 days leading up to the earnings, and a -1.01% change 10 days following the report. On the earnings day itself, the stock moves by +0.91%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -6.18% on the day following the earnings release and then changed by -7.92% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings Call Summary
Neutral
2025-03-03
The earnings call presents a mixed picture: strong year-over-year revenue growth and a decrease in net loss are positive, but lack of current revenue and a net loss remain concerns. The Q&A section reveals uncertainty in regulatory timelines and data disclosures, which can dampen investor confidence. Although there's optimism about paltusotine's market potential and strategic preparations, the absence of immediate revenue and regulatory risks balance out the positives. Given the mid-cap status of Crinetics, the stock is likely to experience a neutral movement in the short term.
Crinetics Pharmaceuticals Inc (CRNX) Q4 2024 Earnings Call Summary
Negative
2025-02-28
The earnings call reveals significant financial challenges, including a sharp revenue decline and increased net losses. Despite having substantial cash reserves, the anticipated high cash burn for 2025 raises concerns. The Q&A section highlights management's lack of clarity on timelines and specifics, which may further unsettle investors. Given these factors and the mid-sized market cap, a negative stock price reaction is likely over the next two weeks.
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Summary
Neutral
2024-11-13
The earnings call showed mixed signals. Financially, the company has strengthened its cash position through a significant equity offering, but it reported a net loss and increased expenses. The absence of revenue and regulatory uncertainties pose risks. The Q&A section highlighted management's reluctance to provide specific timelines, which may raise investor concerns. However, the launch preparation for paltusotine and a strong cash position are positives. Considering the market cap, a neutral stock price movement is expected in the short term.
People Also Watch

EE
Excelerate Energy Inc
25.190
USD
+2.03%

APAM
Artisan Partners Asset Management Inc
44.630
USD
-2.38%

ESE
ESCO Technologies Inc
195.410
USD
+0.94%

USLM
United States Lime & Minerals Inc
111.500
USD
-0.89%

HL
Hecla Mining Co
5.830
USD
-3.16%

MP
MP Materials Corp
60.850
USD
+0.98%

CATY
Cathay General Bancorp
45.870
USD
-1.63%

RNA
Avidity Biosciences Inc
36.880
USD
+2.59%

CRSP
CRISPR Therapeutics AG
57.680
USD
-2.27%

SMPL
Simply Good Foods Co
31.100
USD
-1.36%
FAQ

What were the key highlights of CRNX’s latest earnings report for FY2025Q2?
CRNX reported its FY2025Q2 earnings on 2025-08-07, showcasing a revenue of 0.00 against an estimate of 5.10M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -1.13 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

How did CRNX’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for CRNX for 2025/Q2?

How does CRNX’s stock price correlate with earnings forecast revisions?

What should investors expect from CRNX’s next earnings report?
